Status and phase
Conditions
Treatments
About
The aim of the study is to test the implication of esomeprazole as a possible potential therapy for patients with NASH through evaluating its effect on ultrasound and fibrosis risk scores, serum levels of liver fibrosis biomarkers (fibronectin 1), insulin resistance, metabolic and inflammatory parameters.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Both males and females.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
46 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
aya hesham eltabbakh, bachelor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal